At Carisma we are focused on three principles of work to make engineered myeloid cell therapy a reality: • Testing and validating our foundational scientific perspective • Redefining manufacturing • Fueling, amplifying and extending our platform’s capabilities through thoughtful partnerships Register for our upcoming webcast to learn about how these principles are guiding our latest efforts to leverage the CAR-Macrophage platform: https://bit.ly/39dHRwm
Carisma Therapeutics
Biotechnology Research
Philadelphia, Pennsylvania 13,887 followers
Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors
About us
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA.
- Website
-
http://carismatx.com
External link for Carisma Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Philadelphia, Pennsylvania
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
3675 Market St, Ste 401
Philadelphia, Pennsylvania 19104, US
Employees at Carisma Therapeutics
Updates
-
We are excited to announce the addition of two distinguished leaders, Dr. Scott Friedman and Dr. Ira Tabas, to Carisma’s Scientific Advisory Board! Dr. Friedman and Dr. Tabas bring extensive expertise and pioneering contributions in liver fibrosis, which will be instrumental as Carisma continues its program to develop transformative treatments for patients. We extend our warm welcome to Dr. Scott Friedman and Dr. Ira Tabas! Read more in the press release here: https://lnkd.in/e37JqitW
-
Today, at the 3rd Annual In Vivo Cell Engineering & Gene Editing Summit in Boston, Chief Scientific Officer Michael Klichinsky, PhD, will present on the CAR-M platform. Head to the event website for a full schedule of events and to register: https://lnkd.in/gkQJzZTX
-
-
We are excited to announce new additions to the Board of Directors at Carisma! Marella Thorell and David Scadden. bring vast experience from the life science sector that will be instrumental in advancing our cell therapy platform focused on engineered macrophages. We extend our warm welcome to Marella Thorell and David Scadden! Read more in the press release here: https://lnkd.in/ePx5giz7
Carisma Therapeutics Announces Changes to its Board of Directors | Carisma Therapeutics Inc.
ir.carismatx.com
-
We are excited to announce the nomination of the first Development Candidate under our collaboration with Moderna, Inc. The Development Candidate is an in vivo CAR-M targeting Glypican-3 and is designed to treat solid tumors, including hepatocellular carcinoma, the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the U.S. Read more in the press release here: https://lnkd.in/gpeaEx_v #Immunotherapy #CancerResearch #SolidTumors #LiverCancer #HCC
-
-
Carisma Therapeutics reposted this
We are excited to announce that that the U.S. FDA has granted Fast Track Designation for CT-0525, an ex vivo gene-modified autologous CAR-Monocyte cellular therapy intended to treat HER2-overexpressing solid tumors. This marks a significant milestone for Carisma, highlighting the FDA's recognition of the serious and life-threatening nature of these malignancies and the potential of CT-0525 to meet this critical medical need. Read more in the press release here: https://lnkd.in/gqd93wxq #immunotherapy #oncology
-
-
We are excited to announce that that the U.S. FDA has granted Fast Track Designation for CT-0525, an ex vivo gene-modified autologous CAR-Monocyte cellular therapy intended to treat HER2-overexpressing solid tumors. This marks a significant milestone for Carisma, highlighting the FDA's recognition of the serious and life-threatening nature of these malignancies and the potential of CT-0525 to meet this critical medical need. Read more in the press release here: https://lnkd.in/gqd93wxq #immunotherapy #oncology
-
-
Tune in today at 3:00 pm ET for Carisma Therapeutics Chief Executive Officer Steven Kelly's fireside chat at the Jefferies Global Healthcare Conference. A link to the webcast is available on the investor section of our website: https://bit.ly/3TvbKNh
-
-
Today, we announced that Carisma Therapeutics Chief Executive Officer Steven Kelly is participating in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 from 3-3:25pm ET. For full details and a link to the webcast, read today’s press release: https://lnkd.in/gGScVfh5
-
-
Today at 5:00 pm ET, Michael Klichinsky PhD, will participate in the “Commercializing In Vivo Cell and Gene Therapies” panel discussion at the 2024 #PEGSummit. Check out the event website for a full list of panelists and more information: https://www.pegsummit.com/ #genetherapy
-